Active Ingredient History
Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Intermittent Claudication (approved 2004)
Acute Coronary Syndrome (Phase 4)
Alzheimer Disease (Phase 4)
Angina Pectoris (Phase 3)
Angina, Stable (Phase 4)
Angioplasty, Balloon, Coronary (Phase 4)
Anti-Inflammatory Agents (Phase 4)
Antiphospholipid Syndrome (Phase 4)
Arterial Occlusive Diseases (Phase 4)
Arteriosclerosis Obliterans (Phase 4)
Arthritis, Rheumatoid (Phase 3)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Blood Platelet Disorders (Phase 3)
Blood Platelets (Phase 3)
Brain Ischemia (Phase 4)
Breast Neoplasms (Phase 1/Phase 2)
CADASIL (Phase 1/Phase 2)
Cardiovascular Diseases (Phase 4)
Carotid Artery Diseases (Phase 4)
Cerebral Infarction (Phase 4)
Cerebral Small Vessel Diseases (Phase 4)
Cerebrovascular Disorders (Phase 4)
Chronic Limb-Threatening Ischemia (Phase 4)
Cognitive Dysfunction (Phase 2)
Contraception (Phase 2)
Coronary Artery Disease (Phase 4)
Coronary Restenosis (Phase 4)
Coronary Stenosis (Phase 3)
Dementia, Vascular (Phase 4)
Diabetes Complications (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 1)
Endovascular Procedures (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 3)
Heart Failure, Diastolic (Phase 2)
Hemodialysis, Home (Phase 4)
Hemorrhage (Phase 4)
Hypercholesterolemia (Phase 4)
Hyperlipidemias (Phase 4)
Intermittent Claudication (Phase 4)
Intracranial Aneurysm (Phase 4)
Intracranial Hemorrhages (Phase 4)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Metabolic Syndrome (Phase 4)
Migraine with Aura (Early Phase 1)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardial Reperfusion Injury (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 1/Phase 2)
Osteoarthritis (Phase 1/Phase 2)
Pain (Phase 1)
Percutaneous Coronary Intervention (Phase 4)
Peripheral Arterial Disease (Phase 4)
Peripheral Nervous System Diseases (Phase 1/Phase 2)
Peripheral Vascular Diseases (Phase 4)
Platelet Aggregation Inhibitors (Phase 4)
Polyneuropathies (Phase 4)
Raynaud Disease (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Reperfusion (Phase 2)
Stroke (Phase 4)
Stroke, Lacunar (Phase 2/Phase 3)
Subarachnoid Hemorrhage (Phase 4)
Therapeutic Equivalency (Phase 1)
Therapeutics (Phase 4)
Thrombosis (Phase 4)
White Matter (Phase 1/Phase 2)
Wound Healing (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
